Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Expands By 281.6%

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 31,620 shares, an increase of 281.6% from the June 15th total of 8,286 shares. Based on an average daily trading volume, of 93,974 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are short sold.

Lonza Group Trading Down 0.5%

Shares of OTCMKTS LZAGY traded down $0.34 during mid-day trading on Tuesday, reaching $71.59. The company’s stock had a trading volume of 29,923 shares, compared to its average volume of 82,015. The stock has a 50-day moving average of $64.20 and a two-hundred day moving average of $65.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77. Lonza Group has a 1-year low of $58.53 and a 1-year high of $73.85.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Lonza Group currently has a consensus rating of “Moderate Buy”.

View Our Latest Stock Analysis on LZAGY

Lonza Group Company Profile

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Further Reading

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.